Trial Profile

Tumor-Associated Antigen (TAA) Specific Cytotoxic T Lymphocytes Administered in Patients With Pancreatic Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Neldaleucel (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions
Acronyms TACTOPS

Most Recent Events

07 Feb 2022 Planned End Date changed from 1 Nov 2025 to 1 May 2027.
07 Feb 2022 Planned primary completion date changed from 1 May 2021 to 1 Jan 2023.
31 May 2020 Results (n=13) assessing safety and feasibility of MultiTAA-specific T cell therapy in combination with standard-of-care chemotherapyin advanced or metastatic pancreatic adenocarcinoma, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com